AML･FPCA：米Cardinal Health､SECに880万ドル支払：中国子会社FCPA違反（動画）：
Cardinal Health pays SEC $8.8 million to settle China FCPA offenses：
Cardinal Health向SEC支付了880万美元以了结中国FCPA违法行为
Cardinal Health､中国子会社：FCPA違反
金曜日、中国子会社のFCPA違反で、SECに罰金880万ドルを支払いました。
内部管理命令：、
SECは、FCPAの帳簿記録、内部会計管理規定違反で、Cardinal Healthを告発。
Cardinal Healt：（支払い内訳）
SECと、先ず540万ドルの違反金を支払い、更に､916,887ドル/判決前利息、250万ドル/民事罰の追徴。
Cardinal：
entered the Chinese market in November 2010 when it acquired a company that was later re-branded as Cardinal China.
After it was acquired, Cardinal China abruptly terminated at least two third-party marketing accounts amid allegations that they had been used to facilitate improper payments.
In one instance, a marketing account it administered for a UK- based pharmaceutical manufacturer was terminated in 2013 after Cardinal’s CEO received an internal report alleging that
Cardinal China employees were using the account to “bribe employees of China’s Center for Disease Control.”
Cardinal China also operated marketing accounts for a European supplier of non-prescription, over-the-counter dermocosmetic products for which Cardinal China was the exclusive distributor in China.
Cardinal employed 2,400 people on the European company’s behalf, the SEC said.
According to the SEC,
Cardinal determined that other marketing accounts should be terminated because of their significant FCPA-related compliance risks, but the company “inaccurately assessed the risks of the arrangements with the dermocosmetic company as minimal” and didn’t apply its full internal accounting controls to those accounts.
As a result, some critical employees didn’t receive FCPA and anti-bribery training, and weren’t properly supervised when they dealt with third parties in China.
The FCPA Blog
https://fcpablog.com/2020/02/28/cardinal-health-pays-sec-8-8-million-to-settle-china-fcpa-offenses/
SEC.gov | SEC Charges Cardinal Health With FCPA Violations